| Year |
Title |
Publication |
Support |
|
2021
|
Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells |
Cancer Research Communications |
Funding, Models |
| Molecular features and vulnerabilities of recurrent chordomas |
Journal of Experimental & Clinical Cancer Research |
Data, Prize |
| Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma |
Scientific Reports |
Models |
| Phase 1 open-label trial of intravenous administration of MVA-BN-brachyuryTRICOM vaccine in patients with advanced cancer |
Journal for ImmunoTherapy of Cancer |
Clinical Trial Support |
| Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma |
The Oncologist |
Clinical Trial Support |
| Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models |
Cells |
Models |
| DNA Methylation based prognostic subtypes of chordoma tumors in tissue and plasma |
Neuro-Oncology |
Funding, Models |
| AZD8055 enhances in vivo efficacy of afatinib in chordomas |
Journal of Pathology |
Funding, Models |
| Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity |
Cell Reports Medicine |
Funding, Models |
|
2020
|
Defective HLA Class I expression and patterns of lymphocyte infiltration in chordoma tumors |
Clinical Orthopaedics and Related Research |
Funding |
| The mutational landscape of spinal chordomas and their sensitive detection using circulating tumor DNA |
Neuro-Oncology Advances |
Funding |
| Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death |
Cancer Research |
Funding, Models |
| The sacral chordoma margin |
European Journal of Surgical Oncology |
Authorship |
| Synergistic drug combinations and machine learning for drug repurposing in chordoma |
Scientific Reports |
Models |
| Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma |
Journal of Pathology |
Funding, Models |
| Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy |
Journal of Neuro-Oncology |
Models, Data |
|
2019
|
Distinctive role of dysregulated miRNAs in chordoma cancer stem-like cell maintenance |
Experimental Cell Research |
Models |
| Combination of PARP inhibitor and temozolomide to suppress chordoma progression |
Journal of Molecular Medicine |
Models |
| Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma |
Journal of Medicinal Chemistry |
Models |
| Small-molecule targeting of brachyury transcription factor addiction in chordoma |
Nature Medicine |
Funding, Models, Authorship |
|
2018
|
CDK4 expression in chordoma: A potential therapeutic target. |
Journal of Orthopaedic Research |
Models |
| Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition |
Journal for ImmunoTherapy of Cancer |
Models |
| Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. |
Journal of Neurosurgery |
Models |
| Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma |
Neuro-oncology |
Models |
| Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor? |
Histochemistry and Cell Biology |
Models |
| A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab |
Journal of Neurosurgery |
Models |
| U-CH17P, -M and -S, a new cell culture system for tumor diversity and progression in chordoma |
International Journal of Cancer |
Prize |
| Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury |
Molecular Cancer Therapeutics |
Models, Data, Authorship |
|
2017
|
Emerging opportunities for target discovery in rare cancers |
Cell Chemical Biology |
Data |
| The driver landscape of sporadic chordoma |
Nature Communications |
Funding, Models, Authorship |
| Establishment and genomic characterization of the new chordoma cell line Chor-IN-1 |
Scientific Reports |
Models, Prize |
| Validation of reference genes in human chordoma |
Surgical Neurology International |
Funding, Models |
| UM-Chor1: establishment and characterization of first validated clival chordoma cell line |
Journal of Neurosurgery |
Models, Prize |
| Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group |
Annals of Oncology |
Funding, Authorship |
| Notochord isolation using laser capture microdissection |
Journal of Chemical Neuroanatomy |
Funding |
| Integrated and quantitative proteomics of human tumors |
Methods of Enzymology |
Funding |
| Symptom burden and life challenges reported by adult chordoma patients and their caregivers |
Quality of Life |
Data, Authorship |
|
2016
|
STAT3 inhibition as a therapeutic strategy for chordoma |
Journal of Neurological Surgery |
Models |
| Establishment of clival chordoma cell line-MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies |
Scientific Reports |
Prize |
| IKK/NF-kB signaling contributes to glioblastoma stem cell maintenance |
Oncotarget |
Models, Authorship |
| EGFR inhibitors identified as potential treatment for chordoma in a focused compound screen |
The Journal of Pathology |
Models, Data |
|
2015
|
Building a global consensus approach to chordoma: a position paper from the medical and patient community |
The Lancet Oncology |
Funding, Authorship |
| Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas |
Epigenetics |
Models |
| Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma |
Oncotarget |
Models |
| MicroRNA-155 expression is independently predictive of outcome in chordoma |
Oncotarget |
Funding, Models |
| Phase 1 trial of yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury |
Cancer Immunology Research |
Clinical Trial Support |
| Preclinical characterization of novel chordoma cell systems and their targeting by pharmacological inhibitors of the CDK4/6 cell-cycle pathway |
Cancer Research |
Prize |
| Combined PDGFR and HDAC inhibition overcomes PTEN disruption in chordoma |
PLoS ONE |
Models |
|
2014
|
PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment |
Journal of Neuro-Oncology |
Funding, Models |
| The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival |
Carcinogenesis |
Models |
| Investigating microenvironmental regulation of human chordoma cell behavior |
PLoS ONE |
Funding, Models |
| Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma |
Journal of Orthopaedic Research |
Funding, Models |
| FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation |
Oncotarget |
Models |
| Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines |
Journal of Neurosurgery: Spine |
Models |
| Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma |
Human Genetics |
Funding |
|
2013
|
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies |
Neuro-Oncology |
Funding |
| Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma |
Journal of Neurosurgery |
Prize |
| Erlotinib inhibits growth of a patient-derived chordoma xenograft |
PLoS ONE |
Funding |
| A novel chordoma xenograft allows in vitro drug testing and reveals the importance of NF-kB signaling in chordoma biology |
PLoS ONE |
Funding |
| MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas |
Journal of Neuro-Oncology |
Models |
| Identification of repurposed small molecule drugs for chordoma therapy |
Cancer Biology & Therapy |
Models, Authorship |
|
2012
|
An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma |
Journal of Pathology |
Models |
| A common single-nucleotide variant in T is strongly associated with chordoma |
Nature Genetics |
Funding |
| Characterization of cancer stem-like cells in chordoma |
Journal of Neurosurgery |
Models |
| Controlled release of doxorubicin from PH-responsive microgels |
Acta Biomaterialia |
Models |
|
2011
|
The effects of chemotherapeutic agents on differentiated chordoma cells |
Journal of Neurosurgery: Spine |
Models |
| In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions, and chemotherapeutic drugs |
Radiation Oncology |
Models |
| Massive genomic rearrangement acquired in a single catastrophic event during cancer development |
Cell |
Funding |
| Role of transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional based study |
Journal of Pathology |
Funding, Models |
|
2010
|
Molecular characterization of putative chordoma cell lines |
Sarcoma |
Funding, Authorship |
| Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma |
Journal of Pathology |
Authorship |
|
2009
|
T (brachyury) gene duplication confers major susceptibility to familial chordoma |
Nature Genetics |
Funding |
| Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas |
Clinical Cancer Research |
Models |
